Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen
نویسندگان
چکیده
منابع مشابه
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
PURPOSE Purine analogs and alkylators are important agents for treating chronic lymphocytic leukemia (CLL). Early studies combining fludarabine and chlorambucil were abandoned owing to increased toxicity from overlapping myelosuppression and immunosuppression. Of the purine analogs active in CLL, pentostatin appears to be the least myelosuppressive. We previously reported that pentostatin and c...
متن کاملSevere Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
BACKGROUND/AIMS The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. METHODS A retrospective analysis of pulmonary infection and drug-induced interstitial pneumonitis (DIIP) was per...
متن کاملRituximab versus cyclophosphamide for ANCA-associated vasculitis.
BACKGROUND Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen. METHODS We conducted a multicenter, randomized, double-blind, double-dummy, noninferior...
متن کاملKey words: Vasculitis, treatment, cyclophosphamide, rituximab, ANCA
Medizinische Klinik, Kreiskliniken Esslingen, Plochingen, Germany. Please address correspondence and reprint requests to: Prof. Dr. med. Bernhard Hellmich, Kreiskliniken Esslingen, Klinik Plochingen, Medizinische Klinik, Am Aussichtsturm 5, 73207 Plochingen, Germany. E-mail: [email protected] Received on January 21, 2010; accepted on February 1, 2010. Clin Exp Rheumatol 2010: 28 (Suppl. 57): ...
متن کاملWhat's new in the management of chronic lymphocytic leukemia? 2008 ASH Review (New York Medical College, January 31, 2009)
43 [1] retrospectively compared results of a phase II study of pentostatin and rituximab (PR) to previously published results using pentostatin, cyclophosphamide and rituximab (PCR) [2]. The pentostatin dose was increased to 4 mg/m2 in the PR regimen, but demographics of patients in both studies were similar [1]. Overall response rate (OR) and complete response (CR) rates were similar for PR (7...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hospital Pharmacy
سال: 2016
ISSN: 0018-5787,1945-1253
DOI: 10.1310/hpj5111-888